GB HealthWatch is a San Diego-based genetic-based preventive health company that develops technologies to study molecular mechanisms and translate genetic insights into personalized prevention and treatment strategies for complex diseases. The company raised $3.5M in a pre-Series C funding round. Investors in the round were Trinity Power LLC (a Series B investor) and the company’s founder. Proceeds will be used to grow its national leadership in advanced genetic testing and to develop precision medicine applications targeting dyslipidemia, coronary heart disease, type 2 diabetes, and Alzheimer’s disease. The company also plans to build the infrastructure of its preventive health ecosystem and further develop a platform to enable physicians to prescribe genomics-guided precision therapeutics. GB HealthWatch offers GBinsight genetic testing and analysis, the HealthWatch 360 mobile app and online tool, and the HealthWatch 360 Research Portal for academics, clinicians, and research institutes. The company is led by Dr. Li Shen (President) and Dr. Mendel Roth (Lead Scientist of Genetics and Molecular Biology).

Total raised

$4M

Funding rounds

1

Latest round

Series C

Latest activity

Jan 2022